ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A record number of generic drugs—more than 700—were awarded either final or tentative approval in 2015, FDA says in a recent report. An annual report issued by the Office of Generic Drugs shows that 580 generic drugs were cleared for marketing and another 148 were tentatively approved during the year. FDA issues a tentative approval letter to a generic product applicant when the patents on the original brand-name medicine have not yet expired. A product that has tentative approval cannot be sold in the U.S. The report indicates that FDA rejected nearly 1,300 generic drug applications in 2015 and directed the manufacturers to fix problems. The agency, meanwhile, has essentially eliminated a backlog that once included more than 1,100 applications and is able to inform companies within about 40 days whether their application is sufficient for a full FDA review. In addition, the report touts FDA’s science initiatives to help the generics industry develop products that currently exist only in brand-name form. These include drugs that are inhaled or applied topically and are difficult to reproduce.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter